GSK PLC on Tuesday said it intends to sell around £1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.
Brentford, West London-based pharmaceutical company GSK said it will sell around 300 million shares in Haleon, around 3.2% of its investee’s share capital. At current market prices, the shares being sold are worth £1.00 billion.
Shares in GSK closed down 0.1% to 1,579.20 pence each in London on Tuesday, while Haleon shares closed down 0.1% to 333.80p each.
Following the demerger and listing of Haleon in July 2022, GSK initially retained a 13% stake in Haleon.
After disposals in May and October last year, this was reduced to 7.4% through the aggregate sale of 510 million shares.
This will now be reduced to around 4.2%, after a placing of shares under disposal to institutional investors.
GSK and Pfizer Inc, a New York-listed pharmaceutical firm which holds a 32% stake in Haleon, have both agreed to not dispose of any shares in the company for a period of 60 days after the date of settlement of the latest sale.
Pfizer shares were down 0.8% to $28.46 each in New York around midday.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
